KEYPOINTS: The FDA has granted orphan drug designation (ODD) to CT120 for the treatment of acute lymphoblastic leukemia, a novel chimeric antigen…
ChemRobotics Pvt. Ltd. © 2023, All Rights Reserved.
Designed and Developed by Ample eBusiness
Tag:
Acute
-
-
CompaniesNovartis
Novartis’s BLA has been accepted by US FDA & EMA for Kymriah (Tisagenlecleucel) to treat patients with relapsed or refractory follicular lymphoma.
by adminby adminNovartis says that the U.S. and European regulators have accepted its marketing applications for CAR-T cell therapy Kymriah (Tisagenlecleucel) as third-line therapy…